Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in CLL Patients
NCT06364033Not yet recruiting
- Sponsor
- GIMEMA
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by GIMEMA. Primary endpoint: Serologic response evaluation at 1 month. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06364033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364033.